All Stories

  1. Toward Pathology-guided Illumination Optimization for Neuromodulation with PhomiNeuro
  2. Multimodal neuroimaging elucidates the posterior-to-anterior gradient of nigrostriatal degeneration in Parkinson’s disease
  3. Targeting the crosstalk between Alzheimer’s disease and gastrointestinal cancers
  4. Transcranial pulse stimulation modulates spectral signatures of Alzheimer’s disease in the 3×Tg-AD mouse model
  5. White matter 18F-florbetapir retention predicts cognitive decline and treatment response in Alzheimer’s disease
  6. Divergent scalp-to-region distance alteration patterns in autism spectrum disorders, Parkinson’s disease and Alzheimer’s disease
  7. Design, synthesis, and characterization of F-18 sigma-1 receptor radiotracers for Alzheimer disease
  8. In vivo measures of glutamate and the excitation/inhibition imbalance in brain disorders
  9. Multimodal imaging-guided precise neuromodulation for Alzheimer’s disease
  10. Targeting HSP90 in cancer: advances in the development of inhibitors, mechanisms of action, and therapeutic applications
  11. [18F]florbetapir PET for early detection of amyloidosis in patients with hereditary transthyretin amyloidosis polyneuropathy
  12. Editorial: Update on the diagnosis, treatment, and research of cerebral cavernous malformations
  13. Integration of functional magnetic resonance imaging and artificial intelligence in Alzheimer’s disease
  14. Brain Extracellular Space: From an Overlooked Dimension to Catalyst of a Novel Neuroscience Paradigm
  15. Isoliquiritigenin Attenuates Tau-Associated Neuroinflammation by Inhibiting NLRP3 Inflammasome Activation in Alzheimer’s Disease
  16. Enhanced ex vivo 3D whole-brain mapping and automated analysis of Parkinson’s disease pathologies in mice
  17. Noninvasive imaging of amyloid‐beta and tau in rodent and nonhuman primate models
  18. Plasma growth-associated protein 43 correlates with synaptic loss in Alzheimer’s disease
  19. Investigating the Association Between P2Y12 Receptor, SV2A, and Tau Expression in Postmortem AD and Control Brains Using In Vitro Autoradiography
  20. Multi‐scale imaging of α‐synuclein, dopamingeric neurodegeneration and microstructural changes in α‐synuclein PFF mouse model of Parkinson's disease
  21. Increased levels of GFAP and purinergic P2X7 receptor in Alzheimer’s disease brain are associated with Aβ, tau pathologies and synaptic loss
  22. Transcranial pulse stimulation modulates neuronal activity and functional network dynamics
  23. Chemerin-CMKLR1 differentially mediated OGD/R-induced mitochondrial dysfunction, oxidative stress, and autophagy in microglia and neurons
  24. Discerning Amyloid-β and Tau Pathologies with Learning-Based Quantum Sensing
  25. Non-invasive large-scale imaging of concurrent neuronal, astrocytic, and hemodynamic activity with hybrid multiplexed fluorescence and magnetic resonance imaging (HyFMRI)
  26. Reduced synaptic vesicle protein 2A in extracellular vesicles and brains of Alzheimer’s disease: associations with Aβ, tau, synaptic proteins and APOE ε4
  27. Spinal cord imaging in preclinical research
  28. Isoliquiritigenin attenuated cognitive impairment, cerebral tau phosphorylation and oxidative stress in a streptozotocin-induced mouse model of Alzheimer's disease
  29. Head-to-head comparison of [18F]florbetapir and [18F]FDG PET for the early detection of amyloidosis in systemic amyloidosis and plasma cell dyscrasias
  30. Synthesis and in vivo biological characterization of six carbon-11 sigma-1 receptor radiotracers in rodent and nonhuman primate
  31. Chemerin-CMKLR1 mediated OGD/R induced Mitochondrial Dysfunction, Oxidative Stress, and Autophagy differentially in Microglia and Neurons
  32. Synaptic loss pattern is constrained by brain connectome and modulated by phosphorylated tau in Alzheimer’s disease
  33. Prediction of longitudinal synaptic loss in Alzheimer's disease using tau PET and plasma biomarkers
  34. Imaging alpha-synuclein pathology in Parkinson’s disease
  35. Tau pathology is associated with postsynaptic metabotropic glutamate receptor 5 (mGluR5) in early Alzheimer's disease in a sex‐specific manner
  36. Multimodal imaging of murine cerebrovascular dynamics induced by transcranial pulse stimulation
  37. Biomarkers for synaptic dysfunction in Alzheimer’s disease
  38. Applications of Positron Emission Tomography (PET) in Preclinical Research
  39. Distinguishing Alzheimer’s Pathologies with Machine Learning-Aided Quantum Sensing
  40. Hybrid fluorescence and magnetic resonance imaging (HyFMRI) platform for functional neuroimaging
  41. Development of a novel radioiodinated compound for amyloid and tau deposition imaging in Alzheimer's disease and tauopathy mouse models
  42. Imaging of amyloid, tau and synaptic dysfunction in the brains of type 2 diabetic rats ‐ a multitracer PET study
  43. mTOR inhibition alleviated tau phosphorylation-induced mitochondrial impairment, oxidative stress, and cognitive impairment
  44. Spiral volumetric optoacoustic tomography of reduced oxygen saturation in the spinal cord of M83 mouse model of Parkinson’s disease
  45. Myricetin ameliorates cognitive impairment in 3×Tg Alzheimer’s disease mice by regulating oxidative stress and tau hyperphosphorylation
  46. Effect of APOE ɛ4 Status on Brain Amyloid‐β and Cognitive Function in Amnestic and Nonamnestic Mild Cognitive Impairment: A [18F] Florbetapir PET‐CT Study
  47. Visualizing alpha‐synuclein and iron deposition in M83 mouse model of Parkinson's disease in vivo
  48. Efficient characterization of multiple binding sites of small molecule imaging ligands on amyloid-beta, tau and alpha-synuclein
  49. Gastrodin ameliorates synaptic impairment, mitochondrial dysfunction and oxidative stress in N2a/APP cells
  50. In vivo reactive astrocyte imaging using [18F]SMBT-1 in tauopathy and familial Alzheimer's disease mouse models: A multi-tracer study
  51. Increased Cerebral Level of P2X7R in a Tauopathy Mouse Model by PET Using [18F]GSK1482160
  52. Presynaptic density determined by SV2A PET is closely associated with postsynaptic metabotropic glutamate receptor 5 availability and independent of amyloid pathology in early cognitive impairment
  53. Relationship Between Reactive Astrocytes, by [18F]SMBT-1 Imaging, with Amyloid-Beta, Tau, Glucose Metabolism, and TSPO in Mouse Models of Alzheimer’s Disease
  54. Reduced SV2A and GABAA receptor levels in the brains of type 2 diabetic rats revealed by [18F]SDM-8 and [18F]flumazenil PET
  55. NRF2 Deficiency Promotes Ferroptosis of Astrocytes Mediated by Oxidative Stress in Alzheimer’s Disease
  56. Increased regional P2X7R uptake detected by [18F]GSK1482160 PET in a tauopathy mouse model
  57. Advances in non-invasive imaging of proteinopathies in animal models of neurodegenerative diseases
  58. Noninvasive Visualization of Amyloid-Beta Deposits in Alzheimer’s Amyloidosis Mice via Fluorescence Molecular Tomography Using Contrast Agent
  59. Probing Chemical Complexity of Amyloid Plaques in Alzheimer’s Disease Mice using Hyperspectral Raman Imaging
  60. Relationship between reactive astrocytes, by [18F]SMBT-1 imaging, with amyloid-beta, tau, glucose metabolism, and microgliosis in mouse models of Alzheimer’s disease
  61. Imaging increased metabolism in the spinal cord in mice after middle cerebral artery occlusion
  62. Inorganic phosphate exporter heterozygosity in mice leads to brain vascular calcification, microangiopathy, and microgliosis
  63. Collection on molecular imaging in neurodegeneration
  64. Visualizing alpha-synuclein and iron deposition in M83 mouse model of Parkinson’s diseasein vivo
  65. Deep optoacoustic localization microangiography of ischemic stroke in mice
  66. Evaluation of novel anti-CEACAM6 antibody-based conjugates for radioimmunotheranostics of pancreatic ductal adenocarcinoma
  67. Aquaporin 4 is differentially increased and dislocated in association with tau and amyloid-beta
  68. Efficient characterization of multiple binding sites of small molecule imaging ligands on amyloid-beta, 4-repeat/full-length tau and alpha-synuclein
  69. NRF2 deficiency promotes ferroptosis of astrocytes mediated by oxidative stress in Alzheimer’s disease
  70. Automatic analysis of skull thickness, scalp-to-cortex distance and association with age and sex in cognitively normal elderly
  71. Monitoring mouse brain perfusion with hybrid magnetic resonance optoacoustic tomography
  72. PET imaging in animal models of Parkinson’s disease
  73. Coregistered transcranial optoacoustic and magnetic resonance angiography of the human brain
  74. Automatic analysis of skull thickness, scalp-to-cortex distance and association with age and sex in cognitively normal elderly
  75. Gastrodin ameliorates synaptic impairment, reestablishes mitochondrial membrane potential and reduces oxidative stress in N2a/APP cells through ERK1/2 and GSK-3β pathways
  76. ChemR23 signaling ameliorates cognitive impairments in diabetic mice via dampening oxidative stress and NLRP3 inflammasome activation
  77. Simultaneous Functional Magnetic Resonance and Optoacoustic Imaging of Brain‐Wide Sensory Responses in Mice
  78. Hybrid magnetic resonance and optoacoustic tomography (MROT) for preclinical neuroimaging
  79. Automatic image registration of optoacoustic tomography and magnetic resonance imaging based on deep learning
  80. Evaluation of cannabinoid type 2 receptor expression and pyridine-based radiotracers in brains from a mouse model of Alzheimer’s disease
  81. Quercetin reduces APP expression, oxidative stress and mitochondrial dysfunction in the N2a/APPswe cells via ERK1/2 and AKT pathways
  82. Deep learning facilitates fully automated brain image registration of optoacoustic tomography and magnetic resonance imaging
  83. Sensitive ultrawideband transparent PVDF-ITO ultrasound detector for optoacoustic microscopy
  84. Multimodal Noninvasive Functional Neurophotonic Imaging of Murine Brain‐Wide Sensory Responses (Adv. Sci. 24/2022)
  85. Evaluation of CB2R expression and pyridine-based radiotracers in brains from a mouse model of Alzheimer’s disease
  86. Multiscale optical and optoacoustic imaging of amyloid-β deposits in mice
  87. Editorial: Translational imaging in neurodegenerative proteinopathies
  88. Multimodal Noninvasive Functional Neurophotonic Imaging of Murine Brain‐Wide Sensory Responses
  89. Non-invasive visualization of amyloid-beta deposits in Alzheimer amyloidosis mice using magnetic resonance imaging and fluorescence molecular tomography
  90. Noninvasive optoacoustic imaging of the human brain validated with magnetic resonance angiography
  91. Structural MRI Reveals Cervical Spinal Cord Atrophy in the P301L Mouse Model of Tauopathy: Gender and Transgene-Dosing Effects
  92. Amyloid and Tau Positron Emission Tomography Imaging in Alzheimer’s Disease and Other Tauopathies
  93. Recent Technical Advances in Accelerating the Clinical Translation of Small Animal Brain Imaging: Hybrid Imaging, Deep Learning, and Transcriptomics
  94. Non-invasive imaging of tau-targeted probe uptake by whole brain multi-spectral optoacoustic tomography
  95. Emodin Protects SH-SY5Y Cells Against Zinc-Induced Synaptic Impairment and Oxidative Stress Through the ERK1/2 Pathway
  96. Rapamycin Attenuated Zinc-Induced Tau Phosphorylation and Oxidative Stress in Rats: Involvement of Dual mTOR/p70S6K and Nrf2/HO-1 Pathways
  97. The Impact of Uremic Toxins on Alzheimer's Disease
  98. Magnetic Resonance Imaging in Tauopathy Animal Models
  99. Positron Emission Tomography in Animal Models of Tauopathies
  100. Recent Developments in Positron Emission Tomography Tracers for Proteinopathies Imaging in Dementia
  101. Evaluation of Transcranial Optoacoustic Imaging of a Human Brain Phantom
  102. High‐resolution non‐invasive whole brain imaging of tauopathy in a tauopathy mouse model
  103. Arterial spin labeling demonstrates preserved regional cerebral blood flow in the P301L mouse model of tauopathy
  104. Magnetic Resonance Imaging in Animal Models of Alzheimer’s Disease Amyloidosis
  105. Positron Emission Tomography in Animal Models of Alzheimer’s Disease Amyloidosis: Translational Implications
  106. In vivo Imaging of Cannabinoid Type 2 Receptors: Functional and Structural Alterations in Mouse Model of Cerebral Ischemia by PET and MRI
  107. Multimodal Contrast Agents for Optoacoustic Brain Imaging in Small Animals
  108. PET Imaging of Neuroinflammation in Alzheimer’s Disease
  109. In-vitro and in-vivo characterization of CRANAD-2 for multi-spectral optoacoustic tomography and fluorescence imaging of amyloid-beta deposits in Alzheimer mice
  110. The Synaptic Vesicle Protein 2A Interacts With Key Pathogenic Factors in Alzheimer’s Disease: Implications for Treatment
  111. Real-World Outcomes of Revascularization Strategies in Patients With Left Ventricular Dysfunction and Three-Vessel Coronary Disease Stratified by Mitral Regurgitation
  112. In vitro Characterization of the Regional Binding Distribution of Amyloid PET Tracer Florbetaben and the Glia Tracers Deprenyl and PK11195 in Autopsy Alzheimer’s Brain Tissue
  113. In vivo localization optoacoustic tomography (LOT) with particles smaller than red blood cells
  114. Multi-scale optoacoustic molecular imaging of brain diseases
  115. Non-invasive optoacoustic imaging of tau in P301L mice
  116. Transcranial detection of amyloid‐beta at single plaque resolution in vivo with large‐field multifocal illumination fluorescence microscopy
  117. Transcranial detection of tauopathy in vivo in P301L mice with high‐resolution large‐field multifocal illumination fluorescence microscopy
  118. Volumetric multispectral optoacoustic tomography of beta‐amyloid deposits in whole mouse brain
  119. Detection of cerebral tauopathy in P301L mice using high-resolution large-field multifocal illumination fluorescence microscopy
  120. SWI and phase imaging reveal intracranial calcifications in the P301L mouse model of human tauopathy
  121. Whole brain optoacoustic tomography reveals strain-specific regional beta-amyloid densities in Alzheimer’s disease amyloidosis models
  122. Transcranial in vivo detection of amyloid-beta at single plaque resolution with large-field multifocal illumination fluorescence microscopy
  123. Diffusion Tensor Imaging Reveals Whole-Brain Microstructural Changes in the P301L Mouse Model of Tauopathy
  124. Tau deposition is associated with imaging patterns of tissue calcification in the P301L mouse model of human tauopathy
  125. Simulation of fluorescence molecular tomography using a registered digital mouse atlas
  126. Automated registration of magnetic resonance imaging and optoacoustic tomography data for experimental studies
  127. International Photoacoustic Standardisation Consortium (IPASC): overview (Conference Presentation)
  128. fMRI Reveals Mitigation of Cerebrovascular Dysfunction by Bradykinin Receptors 1 and 2 Inhibitor Noscapine in a Mouse Model of Cerebral Amyloidosis
  129. Automated registration for optoacoustic tomography and MRI
  130. BRADYKININ ANTAGONIST NOSCAPINE MITIGATES CEREBROVASCULAR DYSFUNCTION IN THE ARCAβ MOUSE MODEL OF ALZHEIMER’S DISEASE
  131. EVALUATION OF CANNABINOID RECEPTOR 2 PET IMAGING TRACERS IN ALZHEIMER’S DISEASE BRAIN
  132. IN VIVO OPTOACOUSTIC TOMOGRAPHY OF BRAIN AMYLOID DEPOSITS IN AN ARCAβ MOUSE MODEL OF ALZHEIMER’S DISEASE
  133. Positron emission tomography of type 2 cannabinoid receptors for detecting inflammation in the central nervous system
  134. Cortical hypoperfusion and reduced cerebral metabolic rate of oxygen in the arcAβ mouse model of Alzheimer’s disease
  135. Optimization of GERD Therapeutic Regimen Based on ANN and Realization of MATLAB
  136. Noninvasive detection of acute cerebral hypoxia and subsequent matrix-metalloproteinase activity in a mouse model of cerebral ischemia using multispectral-optoacoustic-tomography
  137. Non-invasive detection of matrix-metalloproteinase activity in a mouse model of cerebral ischemia using multispectral optoacoustic tomography
  138. Quantification of amyloid deposits and oxygen extraction fraction in the brain with multispectral optoacoustic imaging in arcAbeta mouse model of Alzheimer's disease
  139. Comparative In Vitro and In Vivo Quantifications of Pathologic Tau Deposits and Their Association with Neurodegeneration in Tauopathy Mouse Models
  140. In Vivo Visualization of Tau Accumulation, Microglial Activation, and Brain Atrophy in a Mouse Model of Tauopathy rTg4510
  141. Psychological and neural mechanisms of rotating leadership in teams: the impact of engagement and shared mental model
  142. Amyloid tracers binding sites in autosomal dominant and sporadic Alzheimer's disease
  143. Extracerebral Tissue Damage in the Intraluminal Filament Mouse Model of Middle Cerebral Artery Occlusion
  144. Distinct binding of PET ligands PBB3 and AV-1451 to tau fibril strains in neurodegenerative tauopathies
  145. P2‐257: Radioligand Binding Assays for Comparison of TAU Pet Probes, PBB3 and T807, in Detection of TAU Pathologies in Alzheimer's Disease and PSP Brains, and Neurotoxic TAU Species in a Transgenic Mouse Model
  146. P4‐254: Characterization of regional binding of clinical amyloid tracers in autosomal dominant and sporadic Alzheimer's disease brains and their interactions with resveratrol
  147. Astrocytosis precedes amyloid plaque deposition in Alzheimer APPswe transgenic mouse brain: a correlative positron emission tomography and in vitro imaging study
  148. O4‐02‐05: DIFFERENT TIME COURSE OF ASTROCYTOSIS AND AMYLOID DEPOSITION IN ALZHEIMER'S APPSWE TRANSGENICE MICE: A MULTI‐TRACER MICROPET STUDY
  149. 3H-Deprenyl and 3H-PIB autoradiography show different laminar distributions of astroglia and fibrillar β-amyloid in Alzheimer brain
  150. O2–11–03: Astrocytosis precedes amyloid deposition in Alzheimer's Tg2576 APPswe transgenic mice: A multi‐tracer microPET imaging study
  151. IC‐P‐038: Astrocytosis precedes amyloid deposition in Alzheimer's disease Tg2576 APPswe transgenic mice: A multitracer microPET imaging study
  152. Amyloid tracers detect multiple binding sites in Alzheimer's disease brain tissue
  153. Combination of 18F-FDG PET and Cerebrospinal Fluid Biomarkers as a Better Predictor of the Progression to Alzheimer's Disease in Mild Cognitive Impairment Patients
  154. Modulation of α7 Nicotinic Acetylcholine Receptor and Fibrillar Amyloid-β Interactions in Alzheimer's Disease Brain
  155. P2‐487: Alpha7 nicotinic receptor agonists interrupt the interaction between fibrillar amyloid and nicotinic receptor in Alzheimer's brain
  156. P4‐301: Evolution of fibrillar amyloid in relation to astro‐ and microgliosis and alterations in α7 nicotinic receptors in Alzheimer APPswe mice as studied with multi‐tracer concept
  157. P2‐329: Laminar distributions of fibrillar β‐amyloid and activated astrocytes in Alzheimer's disease autopsy brain: A quantitative autoradiography study
  158. P.1.002 Drug interaction between fibrillar amyloid β and alpha7 nicotinic receptor in Alzheimer brain